Complete regression of choroidal metastasis secondary to non-small-cell lung cancer with intravitreal bevacizumab and oral erlotinib combination therapy

Seong-Woo Kim, Myung Jin Kim, Kuhl Huh, Jae Ryung Oh

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: To report a case of a complete regression of choroidal metastasis secondary to non-small-cell lung cancer (NSCLC). Methods: Retrospective case review of a female patient treated with intravitreal bevacizumab and oral erlotinib combination therapy for choroidal metastases secondary to NSCLC. Best corrected visual acuity (BCVA), fluorescein angiography (FA), optical coherence tomography (OCT), and B-scan ultrasonography were compared during the 4-month treatment period. Results: Four weeks after the third injection of bevacizumab (2.5 mg), the BCVA had improved to 20/40 from 20/200 and the 2 subretinal masses had completely disappeared. FA demonstrated only a retinal pigment epithelial (RPE) window defect with minimal to no leakage. In the B-scan ultrasonography and OCT, no further mass-like lesion was detected. The retina and RPE layer were flattened. Conclusion: Combining intravitreal bevacizumab and oral erlotinib could be another treatment option for patients with choroidal metastasis of NSCLC.

Original languageEnglish
Pages (from-to)411-413
Number of pages3
JournalOphthalmologica
Volume223
Issue number6
DOIs
Publication statusPublished - 2009 Oct 1

Fingerprint

Non-Small Cell Lung Carcinoma
Retinal Pigments
Fluorescein Angiography
Optical Coherence Tomography
Neoplasm Metastasis
Visual Acuity
Ultrasonography
Retina
Therapeutics
Injections
Bevacizumab
Erlotinib Hydrochloride

Keywords

  • Bevacizumab
  • Choroidal metastasis
  • Erlotinib
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

@article{e0135a1b14e447c5a67224c6a4cc44c6,
title = "Complete regression of choroidal metastasis secondary to non-small-cell lung cancer with intravitreal bevacizumab and oral erlotinib combination therapy",
abstract = "Purpose: To report a case of a complete regression of choroidal metastasis secondary to non-small-cell lung cancer (NSCLC). Methods: Retrospective case review of a female patient treated with intravitreal bevacizumab and oral erlotinib combination therapy for choroidal metastases secondary to NSCLC. Best corrected visual acuity (BCVA), fluorescein angiography (FA), optical coherence tomography (OCT), and B-scan ultrasonography were compared during the 4-month treatment period. Results: Four weeks after the third injection of bevacizumab (2.5 mg), the BCVA had improved to 20/40 from 20/200 and the 2 subretinal masses had completely disappeared. FA demonstrated only a retinal pigment epithelial (RPE) window defect with minimal to no leakage. In the B-scan ultrasonography and OCT, no further mass-like lesion was detected. The retina and RPE layer were flattened. Conclusion: Combining intravitreal bevacizumab and oral erlotinib could be another treatment option for patients with choroidal metastasis of NSCLC.",
keywords = "Bevacizumab, Choroidal metastasis, Erlotinib, Non-small-cell lung cancer",
author = "Seong-Woo Kim and Kim, {Myung Jin} and Kuhl Huh and Oh, {Jae Ryung}",
year = "2009",
month = "10",
day = "1",
doi = "10.1159/000229307",
language = "English",
volume = "223",
pages = "411--413",
journal = "Ophthalmologica",
issn = "0030-3755",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Complete regression of choroidal metastasis secondary to non-small-cell lung cancer with intravitreal bevacizumab and oral erlotinib combination therapy

AU - Kim, Seong-Woo

AU - Kim, Myung Jin

AU - Huh, Kuhl

AU - Oh, Jae Ryung

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Purpose: To report a case of a complete regression of choroidal metastasis secondary to non-small-cell lung cancer (NSCLC). Methods: Retrospective case review of a female patient treated with intravitreal bevacizumab and oral erlotinib combination therapy for choroidal metastases secondary to NSCLC. Best corrected visual acuity (BCVA), fluorescein angiography (FA), optical coherence tomography (OCT), and B-scan ultrasonography were compared during the 4-month treatment period. Results: Four weeks after the third injection of bevacizumab (2.5 mg), the BCVA had improved to 20/40 from 20/200 and the 2 subretinal masses had completely disappeared. FA demonstrated only a retinal pigment epithelial (RPE) window defect with minimal to no leakage. In the B-scan ultrasonography and OCT, no further mass-like lesion was detected. The retina and RPE layer were flattened. Conclusion: Combining intravitreal bevacizumab and oral erlotinib could be another treatment option for patients with choroidal metastasis of NSCLC.

AB - Purpose: To report a case of a complete regression of choroidal metastasis secondary to non-small-cell lung cancer (NSCLC). Methods: Retrospective case review of a female patient treated with intravitreal bevacizumab and oral erlotinib combination therapy for choroidal metastases secondary to NSCLC. Best corrected visual acuity (BCVA), fluorescein angiography (FA), optical coherence tomography (OCT), and B-scan ultrasonography were compared during the 4-month treatment period. Results: Four weeks after the third injection of bevacizumab (2.5 mg), the BCVA had improved to 20/40 from 20/200 and the 2 subretinal masses had completely disappeared. FA demonstrated only a retinal pigment epithelial (RPE) window defect with minimal to no leakage. In the B-scan ultrasonography and OCT, no further mass-like lesion was detected. The retina and RPE layer were flattened. Conclusion: Combining intravitreal bevacizumab and oral erlotinib could be another treatment option for patients with choroidal metastasis of NSCLC.

KW - Bevacizumab

KW - Choroidal metastasis

KW - Erlotinib

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=67651006008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651006008&partnerID=8YFLogxK

U2 - 10.1159/000229307

DO - 10.1159/000229307

M3 - Article

C2 - 19628953

AN - SCOPUS:67651006008

VL - 223

SP - 411

EP - 413

JO - Ophthalmologica

JF - Ophthalmologica

SN - 0030-3755

IS - 6

ER -